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Dopamine-b-hydroxylase (DbH) catalyzes the conversion of dopamine to norepinephrine and is released from
sympathetic neurons into the circulation. Plasma-DbH activity varies widely between individuals, and a subgroup
of the population has very low activity levels. Mounting evidence suggests that the DBH structural gene is itself
the major quantitative-trait locus (QTL) for plasma-DbH activity, and a single unidentified polymorphism may
account for a majority of the variation in activity levels. Through use of both sequencing-based mutational analysis
of extreme phenotypes and genotype/phenotype correlations in samples fromAfrican American, EuropeanAmerican
(EA), and Japanese populations, we have identified a novel polymorphism (51021CrT), in the 5′ flanking region
of the DBH gene, that accounts for 35%–52% of the variation in plasma-DbH activity in these populations. In
EAs, homozygosity at the T allele predicted the very low DbH–activity trait, and activity values in heterozygotes
formed an intermediate distribution, indicating codominant inheritance. Our findings demonstrate that51021CrT
is a major genetic marker for plasma-DbH activity and provide new tools for investigation of the role of both DbH
and the DBH gene in human disease.
Dopamine-b-hydroxylase (DbH [MIM 223360]) cata-
lyzes the conversion of dopamine to norepinephrine. It
is localized in catecholamine-containing vesicles of ad-
renergic and noradrenergic cells (Oka et al. 1967; Kem-
per et al. 1987). DbH protein is released in response to
stimulation (Viveros et al. 1968), and DbH activity, de-
rived largely from sympathetic nerves, can be measured
in human plasma (Weinshilboum and Axelrod 1971a;
Weinshilboum 1978). Plasma (or serum) activity levels
vary widely among individuals (Weinshilboum et al.
1973) but are stable within individuals over time (Fahn-
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drich et al. 1982). Family and twin studies have indicated
that the majority of interindividual variability in plasma-
DbH activity is genetically determined (Ross et al. 1973;
Weinshilboum et al. 1973; Oxenstierna et al. 1986).
In a large study of European Americans (EAs), Wein-
shilboum et al. (1975) identified a subgroup, consisting
of 3%–4% of the population, who have very low levels
of plasma-DbH activity. Parents of these individuals
have an average enzyme activity that is intermediate be-
tween the very low DbH–activity subgroup and a pop-
ulation selected at random. Pedigree segregation anal-
yses of these families suggested that the very low
DbH–activity trait is monogenically inherited by an au-
tosomal codominant mechanism (Weinshilboum 1983).
Weinshilboum (1978) postulated the existence, at an un-
specified locus, of a functional low-activity allele, DBHL,
with a frequency of ∼20% in the EA population. A single
locus was estimated to account for 46%–75% of the
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plasma DbH–activity variance in the population (Elston
et al. 1979; Goldin et al. 1982; Wilson et al. 1990).
Studies using protein-phenotype markers showed strong
evidence for linkage between a major locus controlling
plasma-DbH activity and the ABO blood-group locus
(Goldin et al. 1982; Wilson et al. 1988). The DBH gene
was subsequently cloned, mapped to chromosome 9q34,
and shown, by molecular studies, to be linked to ABO
(Lamouroux et al. 1987; Craig et al. 1988; Gelernter et
al. 1991; Perry et al. 1991). Molecular markers at the
DBH locus were then shown to associate with variation
in both plasma-DbH activity (Wei et al. 1997; Cubells
et al. 1998, 2000) and cerebrospinal-fluid (CSF) levels
of immunoreactive DbH protein (Cubells et al. 1998).
Taken together, these findings strongly suggest thatDBH
itself is the major quantitative-trait locus (QTL) for
plasma-DbH activity—and that it contains the DBHL
allele. The molecular identity of the DBHL allele remains
to be determined.
Altered plasma-DbH activity has been reported in a
variety of psychiatric and neurological disorders (Wein-
shilboum and Axelrod 1971b; Lieberman et al. 1972;
Fujita et al. 1978; Matuzas et al. 1982; Nagatsu et al.
1982). Given the evidence summarized above,DBHmay
therefore be an important disease-causing or disease-
modifying candidate gene. Disease-related variation in
DbH activity could be interpreted more readily if the
molecular basis of heritable variation in plasma DbH
were known. Comprehensive studies examining the re-
lationship between polymorphic variation at DBH and
plasma-DbH activity have not been published. Here we
report a sequencing-based mutational analysis of the
DBH gene from subjects with extreme plasma-DbHphe-
notypes. We then examine genotype/phenotype corre-
lations in samples from African American (AA), Japa-
nese (Jp), and EA populations.
Plasma and DNA samples from 58 unrelated AA and
174 unrelated EA subjects (self-identified population
groups; those of mixed or other heritage were excluded)
were collected during the course of several ongoing genetic
studies. The groups included both healthy individuals and
those with psychiatric and substance-abuse disorders. As
discussed elsewhere (Cubells et al. 1998), sampling from
a variety of diagnostic groups is unlikely to obscure fun-
damental genetic influences on plasma-DbH activity.
Plasma and DNA samples were obtained from 53 healthy,
unrelated ethnic-Japanese subjects recruited at the Insti-
tute for Comprehensive Medical Sciences, Fujita Health
University, Toyoake, Japan. All subjects gave informed
consent for participation in molecular-genetic studies.
DbH activity was assayed in plasma samples from all
subjects, as described elsewhere (Cubells et al. 1998).
TheDBH gene is ∼23 kb in length and contains 12 exons
(Kobayashi et al. 1989). The genomic sequence is pub-
licly available (Genbank accession numbers AC000404
and AC001227). We searched for potential functional
polymorphisms by sequencing a total of 6,443 bp of
DBH, including the proximal 1,468 bp of the 5′ up-
stream area, all exons (2,744 bp), and 2,182 bp of in-
tronic sequence, spanning 49 bp flanking each exon.
A minimum of eight individuals were selected to rep-
resent extreme values of DbH activity. This group in-
cluded at least four individuals (two EA and two Jp)
with very low activity (defined here as !2.5 nmol oc-
topamine/min/ml plasma [hereafter expressed as “nmol/
min/ml”]), two EAs with near-average activity, and two
EAs with activity 12 SD above the mean. Twelve sub-
jects, eight (six EA and two Jp) with very low activity,
were included for the sequencing of the proximal 1.0 kb
of the promoter region and of exon 1. Sequencing was
performed, with minor modifications, as described else-
where (Zabetian et al. 2000). PCR primer sequences and
reaction conditions are available on request.
All newly detected polymorphisms that appeared to
aggregate according to DbHactivity in the sequenced sub-
set of samples, as well as all previously described non-
synonymous polymorphisms, were selected as functional
candidates and were genotyped in the entire AA, EA, and
Jp samples. The average rate of PCR nonamplification for
each population-specific genotype group was 1.6%, and
the maximum was 4.0%. Genotypes were determined by
RFLPs, by digestion of PCRproductswith the appropriate
restriction enzymes, as shown in table 1. RFLP genotyping
was confirmed by the sequencing of representative sam-
ples of each polymorphism.
An initial plot of genotypes at1021CrT and of pop-
ulation-specific variance against mean DbH activity pro-
duced three approximately straight lines passing through
the origin (data not shown), suggesting that a square-root
transformation would be appropriate for stabilization of
the variance. Maximum likelihood was therefore used to
fit a Box-Cox power transformation (Box and Cox 1964)
and to test equality of the power parameter to 0.5, on
the assumption of normality and a common variance. On
the basis of the result of this test, an analysis of variance
of square-root DbH activity was used to test for genotype
effects, population effects, and genotype # population
interaction. In addition, deviation from additive gene ac-
tion was tested and was found to be nonsignificant. Be-
cause heritability can be estimated more accurately if
Hardy-Weinberg equilibrium (HWE) can be assumed, de-
viations from HWEwere assessed using the HWSIM pro-
gram (Cubells et al. 1997; also see the HWSIMWeb site).
Since some of the analyses contained small numbers of
observations in some cells, P values for all analyses were
estimated empirically, with Monte Carlo simulations
(10,000 iterations in each case) based on observed allele
frequencies. Significance levels were estimated as the pro-
portion of times that the simulated distribution reached
or exceeded the observed deviation from HWE. Herita-
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Table 1
Allele Frequencies of DBH Polymorphisms in Three Population Samples
LOCATION POLYMORPHISMa
AMINO
ACID
CHANGE
RESTRICTION
SITE FOR
GENOTYPING
MEAN  BINOMIAL SE, FOR ALLELE FREQUENCY IN
AA (2np116) EA (2np348) Jp (2np106)
5′ Flanking 1021CrT … MwoIb .198  .037 .224  .022 .160  .036
Exon 3 499GrCc E167Q BsrI NDd ND ND
Exon 3 589GrAc A197T BstUI .129  .031 .083  .015 .144  .035
Exon 3 675GrCc K225N ApaIb ND ND ND
Exon 4 706GrCc E236Q BanII ND ND ND
Exon 4 826GrAc D276N BsiEI .052  .021 .003  .003 ND
Intron 4 IVS4601TrC … BsmBIb .348  .045 .524  .034 .837  .036
Exon 5 908TrCc L303P BslI ND ND ND
Exon 5 910GrTe A304S MwoI .147  .033 .062  .013 .010  .010
Exon 11 1603CrTe R535C BstUI .035  .017 .043  .011 ND
a Nucleotide positions are numbered according to either cDNA sequence, for exons, or genomic sequence, for the
5′ flanking region, beginning at the A of the ATG initiator Met codon; positions for introns are numbered according
to the genomic sequence, starting from the G of the donor-site invariant GT.
b Artificial restriction site.
c From Halushka et al. (1999).
d NDpnot detected in sample.
e From Kobayashi et al. (1989).
bility was estimated, under the assumption of HWE, as
follows: / , where the ad-2 2 2 2h p [2p(1-p)d ] [2p(1-p)d  s ]
ditive gene effect is d, the gene frequency is p, s2 is the
estimate of the common variance about the genotype
mean, and its standard error is obtained by application
of the large-sample “delta” method (DeGroot 1989), by
double differentiation of the log likelihood to obtain the
variance-covariance matrix of d and s2. A pooled estimate
of heritability was also calculated under the assumption
of HWE, as a weighted average of the individual popu-
lation heritabilities, with weights inversely proportional
to their variances and summing to 1.
The plasma DbH–activity data are summarized in fig-
ure 1. There was a small but statistically significant dif-
ference, in mean activity values, between EAs and Jps
( ), but there were no differences between AAsPp .003
and either Jps or EAs ( ). In the EA group, a clusterP 1 .1
of individuals with activity values !2.5 nmol/min/mlwas
identified by visual inspection of frequency histograms
(fig. 1), and was defined as the “very low DbH–activity”
subgroup. This corresponds closely with the threshold
of !2.6 nmol/min/ml defined by Weinshilboum et al.
(1975) for the very low DbH–activity subgroup (cor-
rected, for differences in methodology, by a factor of
18.9, per Weinshilboum [1978]). This subgroup consti-
tuted 7.5% of EAs and 3.8% of Jps in the present study.
In the AA group, however, no discrete cluster of very
low levels was readily discernible, with 5.2% of the ac-
tivity values !2.5 nmol/min/ml.
The sequencing of the eight individuals representing
phenotypic extremes revealed 18 single-nucleotide poly-
morphisms (SNPs) not previously reported (ID numbers
obtained from the Database of Single Nucleotide Poly-
morphisms). Fourteen of these were located in introns,
four in the 5′ flanking region, and none in the coding
sequence. Themost proximal SNP in the 5′ flanking region
occurred at position 496. Two of these SNPs—one lo-
cated in the 5′ flanking region (1021CrT), the other in
intron 4 (IVS4601TrC)—associated with the very low
DbH–activity subgroup in the sequenced samples and
were included in further genotyping studies of the com-
plete sample populations.
Four of the eight previously described nonsynonymous
SNPs were not detected in any of the three population
samples, and only two (589GrA and 910GrT) occurred
in all three samples (table 1). There were no deviations
from HWE for genotypes at any of the polymorphisms
in either the AA group or the Jp group. In the EA sample,
a small but statistically significant ( ) deviationPp .034
from HWE was seen in genotypes at 1021CrT, but at
none of the other polymorphisms. However, this observed
P value does not reach significance after application of
the Bonferroni correction for three tests.
The 1021CrT polymorphism was strongly associ-
ated with untransformed DbH-activity values in all three
population samples ( ). Because of significantP ! .001
heterogeneity of variance between genotype groups, an
appropriate transformation function was estimated, as
described above. The value of the power parameter was
.5083, whether separate genotypic means or additive
gene effects were fitted, and the nonadditivity (domi-
nance variance) was not significant ( ). This es-Pp .72
timate was not significantly different ( ) from .5,Pp .9
the square-root function. Table 2 gives the population-
/genotype-specific means (and the standard errors of the
mean) for square-root DbH activity. An analysis of var-
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Figure 1 Distribution of plasma-DbH activity in AA (A), EA
(B), and Jp (C). Subjects are grouped in successive 2.5-nmol/min/ml
increments. The hatched bar indicates the results for the very lowDbH-
activity group. The EA and Jp mean activity values differed signifi-
cantly ( , one-way ANOVA; followed by Dunnett C post-hocP ! .01
test).
Table 2
DbH Activity Values Specific to Genotypes at 51021CrT in Three
Population Samples
SAMPLE AND
GENOTYPE (n)
MEAN  SEM
DbH Activity
(nmol/min/ml)
Square-Root
DbH Activity
(square-root nmol/min/ml) h2 a
AA:
TT (4) 6.0  4.2 2.07  .76
CT (15) 15.8  3.7 3.62  .44
CC (39) 39.0  3.7 5.96  .30
Overall .31  .12
EA:
TT (16) 4.1  2.1 1.47  .36
CT (46) 25.2  2.0 4.80  .22
CC (112) 48.1  2.1 6.74  .15
Overall .44  .09
Jp:
TT (1) .4 .66
CT (15) 15.0  1.7 3.79  .21
CC (37) 35.6  1.8 5.85  .20
Overall .52  .28
a Under the assumption of HWE.
iance of square-root DbH activity indicated significant
effects of genotype at1021CrT ( ) and of pop-P ! .001
ulation ( ), but not of genotype # populationP ! .001
interaction ( ). The proportion of variability (R2)Pp .51
due to genotype at 1021CrT was .35, .51, and .52
for the AAs, EAs, and Jps, respectively. Addition of
1603CrT to the model resulted in a small but significant
( ) increase of .02 in R2. The added contri-Pp .0024
bution of the remaining four polymorphisms detected in
our population samples was not significant ( ).P 1 .05
The heritabilities  SE of square-root DbH activity
under the assumption of HWE and additive gene action
were , for AAs; , for EAs; and2h p .31 .12 .44 .09
, for Jps ( for EAs, when there is no2.52 .28 h p .50
assumption of HWE). The overall (mean  SEM) her-
itability was .40  .07 when data from all three pop-
ulations were pooled. Histograms of square-root DbH
activity versus genotype at 1021CrT are presented in
figure 2. In EAs, the TT genotype was strongly associated
( ) with the very low DbH–activity trait, sinceP ! .0001
12 of the 13 subjects with the trait were TT homozy-
gotes. The remaining individual was heterozygous at
1021CrT but was the only subject in any of the three
populations who was homozygous at the nonsynony-
mous exon 11 polymorphism 1603CrT. Four TT ho-
mozygotes had transformed activity values that exceeded
the very low DbH–activity threshold (!1.58 square-root
nmol/min/ml), but all were below the population mean
(5.74 square-root nmol/min/ml). Transformed activity
values in subjects who were heterozygous at1021CrT
formed a distribution intermediate between the two ho-
mozygous groups in the EA and Jp samples, in a way
consistent with autosomal codominant inheritance of the
very low DbH–activity trait (fig. 2).
Several previous population-based studies have found
associations between polymorphisms in the DBH gene
and plasma-DbH activity, in individuals of European
heritage (Wei et al. 1997; Cubells et al. 1998, 2000).
These polymorphisms have included one in the 5′ flank-
ing region (4784–()4803del) and a synonymous SNP
in exon 2 (444GrA). However, the allele frequencies
and distributions of genotype-specific mean activities for
each of these polymorphisms are not compatible with
those predicted for the DBHL allele, and neither of these
previous allelic associations holds in any sample except
the EA sample (J.F.C., C.P.Z., G.M.A., and J.G., un-
published observations). Therefore, these previous as-
Reports 519
Figure 2 Distribution of square-root plasma-DbH activity, by
genotype, at DBH polymorphism 1021CrT in AA (A), EA (B), and
Jp (C). Green bars denote T/T homozygotes, red bars denote C/T
heterozygotes, and blue bars denote C/C homozygotes. A single C/C
homozygote with an extreme activity value of 11.2 square-root nmol/
min/ml was omitted from the EA distribution plot, for the purpose of
graphical clarity.
sociations appear to arise from linkage disequilibrium
(LD) between the examined alleles and nearby functional
variants. In contrast,1021CrT accounts for one third
or more of the variance in plasma-DbH activity, in all
three of the ethnically diverse populations examined in
the present study. Such cross-population consistency in
genotype-phenotype relationships supports a causal as-
sociation between a polymorphism and trait outcome,
rather than an association based solely on LD (Risch
2000). Moreover, the frequency ( ) of the T.224 .022
allele in the EA sample examined here is very close to
the predicted frequency (.20) for DBHL (Weinshilboum
1978). The mean  SEM and range ( and38.0 1.8
0–125 nmol/min/ml) of activity values for EAs in this
study are similar to those obtained in Weinshilboum et
al.’s (1975) study of 227 unrelated healthy adult EAs
( and 0–129.6 nmol/min/ml, corrected as de-36.1 1.5
scribed above). Thus, the present study provides the
strongest evidence yet for the molecular identity of the
DBHL allele, predicted some 25 years ago to account for
a large proportion of the genetic variation in human
plasma-DbH activity.
Several additional considerations suggest that
1021CrT may itself be the major functional poly-
morphism at the DBH locus, accounting for variation
in plasma-DbH activity:
1. The DBHL allele appears to lower plasma-DbH
activity by diminishing the levels of circulating DbHpro-
tein, rather than by decreasing the activity of homo-
specific enzymes (Dunnette and Weinshilboum 1976). A
5′-upstream polymorphism such as 1021CrT, differ-
entially regulatingDBH transcription, would readily ac-
count for this type of biochemical phenotypic variation.
2. Reporter-gene experiments in transgenic mice
suggest that the region between base pair600 and base
pair 1100 contains elements critical for human DBH-
gene expression (Hoyle et al. 1994). To date, specific
cis-acting motifs, including CREB- and Phox2a/2b-bind-
ing sites, have only been identified in more-proximal 5′
flanking regions (Kim et al. 1998).
3. 1021CrT is located in a noradrenergic cell-
type–specific DNase I hypersensitive site of theDBH gene
(Ishiguro et al. 1993).
These observations do not directly demonstrate a func-
tional role for 1021CrT, nor do they rule out the
possibility that LDwith an as-yet-unidentified functional
variant accounts for the strong association with DbH
activity. However, these converging lines of evidence sug-
gesting the testable hypothesis that 1021CrT alters
transcriptional regulation of DBH expression warrant
further study.
In the EA sample, genotypes at 1021CrT deviated
slightly from HWE, with a greater number of TT ho-
mozygotes being observed than were expected, possibly
because of a sampling bias due to the inclusion of sub-
jects with psychiatric illnesses. Regardless of the source
of the deviation, if the TT genotype is associated with
the very low DbH–activity trait, then one would expect
to see that trait in a larger proportion of individuals
within the sample; and this is precisely what was ob-
served: the very low DbH–activity subgroup constituted
a larger proportion of our EA sample (7.5%) than it did
in Weinshilboum et al.’s (1975) study of adult EAs
(3.1%).
The clinical significance of plasma-DbH activity levels
has been the subject of controversy for some time. Initially,
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some 3 decades ago, it was hoped that plasma-DbH ac-
tivity might both provide a direct measure of noradren-
ergic and adrenergic synaptic activity and be a sensitive
indicator of sympathetic function. This idea proved overly
simplistic, since it later became apparent that the wide
individual variation in activity levels is primarily geneti-
cally determined, with estimates of heritability being
.61–.98 (Elston et al. 1979; Oxenstierna et al. 1986; Wil-
son et al. 1990). Also, even extreme manipulations of
sympathetic function, such as cold-pressor stimulation
and strenuous exercise, had minimal effects on plasma-
DbH levels, despite producing large increases in circulat-
ing catecholamines (Winer and Carter 1977; Peronnet et
al. 1985). Yet, these findings do not exclude the role of
plasma DbH as an indicator of long-term trends in—or
of functional reserve of—the sympathetic nervous system.
Our findings in the present study suggest that low plasma-
DbH levels result from diminished expression of theDBH
gene associated with the 1021T allele. Homozygosity
at this allele, resulting in very low plasma-DbH activity,
might likewise limit the maximum potential production
of DbH enzyme within noradrenergic neurons. Normally,
this may have no significant physiological consequences.
However, in disease states in which degeneration of the
sympathetic nervous system occurs, such as in idiopathic
Parkinson Disease (IPD) (Wakabayashi and Takahashi
1997), this may be an important issue; for example, a
growing body of evidence suggests that mild autonomic
dysfunction in IPD is quite common but that severe symp-
toms are rare (Turkka et al. 1986; Magalhaes et al. 1995;
Druschky et al. 2000). Individuals with IPD who are ho-
mozygous for the DBHL allele may have a decreased sym-
pathetic functional reserve and a diminished capacity to
compensate for the loss of adrenergic neurons. These pa-
tients might thus have an earlier onset of—and more se-
vere symptoms of—autonomic dysfunction. Our results
make this hypothesis directly testable.
Within in the field of psychiatry, there has been a great
deal of interest in DBH as a disease-modifying gene and
in plasma-DbH activity as an intermediate trait. Many
conflicting reports on the relationship between plasma/
CSF DbH levels and psychiatric disorders have been
published (Fujita et al. 1978; Meltzer et al. 1980; Ma-
thew et al. 1981; Matuzas et al. 1982; Arato´ et al. 1983).
Since much of the individual variation in plasma-DbH
levels is under genetic control, and since researchers pre-
viously had been unable to account for the genetic com-
ponent of the variance in plasma DbH, such conflicting
results are not surprising. Identification of the putative
functional polymorphism 1021CrT will allow future
clinical studies to evaluate whether DbH-activity differ-
ences in disease groups represent differences in genotype
frequencies at the DBH locus. In addition, controlling
for the large proportion of plasma-DbH variance that
is accounted for by the DBH genotype may unmask
changes in DbH activity that result from illness, medical
treatment, or the influences of other genetic loci. Our
demonstration of the 1021CrT polymorphism as a
major genetic marker for plasma-DbHactivity will allow
the role of the DBH gene in human disease to be eval-
uated in a new light.
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